Prediction of Response to Androgen Deprivation Therapy and Castration Resistance in Primary Metastatic Prostate Cancer

2012 ◽  
Vol 88 (1) ◽  
pp. 25-33 ◽  
Author(s):  
Rauf Taner Divrik ◽  
Levent Türkeri ◽  
Ali F. Şahin ◽  
Bülent Akdoğan ◽  
Ferhat Ateş ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Androgen Deprivation ◽  
Castration Resistance ◽  
Prediction Of Response

scholarly journals Metastatic Prostate Cancer under Androgen Deprivation Therapy: Factors Influencing Castration Resistance

2020 ◽  
Vol 10 (07) ◽  
pp. 225-232
Author(s):  
Modou Ndiaye ◽  
Ousmane Sow ◽  
Babacar Sine ◽  
Omar Gaye ◽  
Alioune Sarr ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Androgen Deprivation ◽  
Castration Resistance ◽  
Factors Influencing

scholarly journals Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer

Cancer ◽  
2018 ◽  
Vol 125 (3) ◽  
pp. 453-462 ◽  
Author(s):  
Hala T. Borno ◽  
Daphne Y. Lichtensztajn ◽  
Scarlett L. Gomez ◽  
Nynikka R. Palmer ◽  
Charles J. Ryan
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Androgen Deprivation

A proposed link between spinal epidural lipomatosis, prostate cancer and androgen deprivation therapy

2017 ◽  
Vol 11 (4) ◽  
pp. 299-301 ◽  
Author(s):  
Isabel Tulloch ◽  
James T Laban ◽  
Andrew J Martin
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Spastic Paraparesis ◽  
Androgen Deprivation ◽  
Vertebral Metastases ◽  
Spinal Epidural Lipomatosis ◽  
Epidural Lipomatosis ◽  
Spinal Epidural

We present a patient with prostate cancer with vertebral metastases who developed spastic paraparesis secondary to spinal epidural lipomatosis (SEL) after receiving androgen deprivation therapy (ADT). We propose a link between ADT, metastatic prostate cancer and SEL.

Management of Metastatic Castrate-sensitive Prostate Cancer

2018 ◽  
Author(s):  
Derya Tilki ◽  
Marc A Dall’era ◽  
Christopher P Evans
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Survival Benefit ◽  
Metastatic Prostate Cancer ◽  
Oncologic Outcome ◽  
Standard Of Care ◽  
Abiraterone Acetate ◽  
Androgen Deprivation ◽  
Newly Diagnosed ◽  
Treatment Paradigm

Oncologic outcome of patients with newly diagnosed metastatic prostate cancer (mPCa) is poor. The treatment paradigm for newly diagnosed mPCa has changed. The standard of care for men with metastatic hormone-naive prostate cancer has been systemic androgen deprivation therapy (ADT). Previous randomized studies demonstrated an overall survival benefit by the addition of early chemotherapy with six cycles of docetaxel. More recently, results from randomized trials also demonstrated a survival benefit by the addition of abiraterone acetate to the ADT in men with metastatic disease. The aim of this review is to summarize the results from most recent studies, including men with newly diagnosed metastatic hormone-naive prostate cancer, focusing on chemotherapy and ADT. This review contains 1 figure, 2 tables, and 47 references.  Key Words: abiraterone acetate, androgen deprivation therapy, androgen deprivation, castrate sensitive, chemotherapy, continuous androgen deprivation, docetaxel, hormone-naive, intermittent androgen deprivation, metastatic prostate cancer

Sign in / Sign up

Export Citation Format

Share Document